Treatment Resistance Depression: Separating It From Comorbidity
## Dextromethorphan/Bupropion (DM/BUP) and Potential Expanded psychiatric Applications
Dextromethorphan/bupropion (DM/BUP) is currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Major depressive Disorder (MDD) and agitation associated with alzheimer’s disease. The source suggests exploration of its use in other psychiatric conditions due to its unique mechanism of action and favorable safety profile. As of January 14,2026,there have been no further FDA approvals for DM/BUP beyond these initial indications,but research continues.
### Dr.Stoner’s outlook on DM/BUP’s Potential
Dr. Stoner, as referenced in the source, believes DM/BUP’s effectiveness in treatment-resistant depression and its safety in vulnerable populations suggest a broader role for the drug. This perspective is rooted in the drug’s action on NMDA and sigma-1 receptors, differentiating it from customary antidepressants that primarily target monoamines.The history of psychopharmacology demonstrates a pattern of drugs initially approved for one condition being repurposed for others, such as antidepressants and antipsychotics being used for anxiety or mood augmentation.
### mechanism of Action and Therapeutic Advantages
DM/BUP’s mechanism of action centers on modulating the N-methyl-D-aspartate (NMDA) receptor and the sigma-1 receptor. Research indicates that NMDA receptor antagonism, combined with sigma-1 receptor agonism, can enhance synaptic plasticity and neurotrophic support, perhaps addressing underlying neurobiological deficits in various psychiatric disorders. This differs from traditional monoaminergic antidepressants, which primarily focus on serotonin, norepinephrine, and dopamine levels. A key advantage highlighted is the potential to avoid side effects common with other treatments, such as metabolic issues and movement disorders associated with antipsychotics, or sedation and fall risks linked to benzodiazepines.
### Cost Analysis and Market Considerations
A poster presentation at the AMCP Nexus conference in October 2025 (referenced in the source) presented a Merative MarketScan cost analysis of patients treated with DM/BUP. While the abstract details are not publicly available as of January 14,2026,the analysis suggests an economic consideration alongside clinical potential.AJMC reported on the presentation, noting the potential for cost savings compared to other treatments, particularly in later lines of therapy. This economic factor could influence adoption in broader patient populations if clinical benefits are demonstrated.
### Regulatory Status and Future Research
As of January 14, 2026, DM/BUP remains approved only for MDD and Alzheimer’s agitation. The official Auvelity website provides current information on approved uses and safety information. Further research is needed to determine the efficacy and safety of DM/BUP in other psychiatric conditions. Clinical trials are likely necessary to support expanded indications and demonstrate a favorable risk-benefit profile for new patient populations. The FDA requires considerable evidence of efficacy and safety before approving new uses for existing drugs.